Hepatorenal syndrome

Common Name(s)

Hepatorenal syndrome

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hepatorenal syndrome" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hepatorenal syndrome" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Hepatorenal syndrome" returned 68 free, full-text research articles on human participants. First 3 results:

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
 

Author(s): A J Sanyal, T D Boyer, R T Frederick, F Wong, L Rossaro, V Araya, H E Vargas, K R Reddy, S C Pappas, P Teuber, S Escalante, K Jamil

Journal: Aliment. Pharmacol. Ther.. 2017 Jun;45(11):1390-1402.

 

The goal of hepatorenal syndrome type 1 (HRS-1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS-1, where it is available.

Last Updated: 3 Apr 2017

Go To URL
TERLIPRESSIN VERSUS NORADRENALINE FOR HEPATORENAL SYNDROME. Economic evaluation under the perspective of the Brazilian Public Health System.
 

Author(s): Ângelo Zambam de Mattos, Angelo Alves de Mattos, Rodrigo Antonini Ribeiro

Journal: Arq Gastroenterol. ;53(2):123-6.

 

- Terlipressin and noradrenaline are the best studied treatments for hepatorenal syndrome, and there is no evidence of superiority of one over the other regarding to efficacy. While the former drug is more costly, the latter requires admission into an intensive care unit.

Last Updated: 16 Jun 2016

Go To URL
Is there any potential or additive effect of anemia on hepatorenal syndrome?
 

Author(s): Gökhan Güngör, Murat Akyıldız, Muharrem Keskin, Yalçın Solak, Abduzhappar Gaipov, Murat Bıyık, Sami Çifçi, Hüseyin Ataseven, Hakkı Polat, Ali Demir

Journal: Turk J Gastroenterol. 2016 May;27(3):273-8.

 

Hepatorenal syndrome (HRS) is a severe complication of advanced cirrhosis and is characterized by renal dysfunction and poor survival rates. Although anemia is a non-rare condition in advanced liver cirrhosis, there is no publication regarding the potential or additive effects of ...

Last Updated: 23 May 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Hepatorenal syndrome" returned 41 free, full-text review articles on human participants. First 3 results:

 Hepatorenal syndrome: Current concepts related to diagnosis and management.
 

Author(s): Ángelo Zambam de Mattos, Angelo Alves de Mattos, Nahum Méndez-Sánchez

Journal: Ann Hepatol. ;15(4):474-81.

 

 Renal failure in cirrhotic patients is a very severe condition. Hepatorenal syndrome has the worst prognosis among all causes of kidney failure in such patients. Hepatorenal syndrome is diagnosed especially in cirrhotic patients with ascites who develop loss renal function, despite ...

Last Updated: 29 May 2016

Go To URL
Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis.
 

Author(s): Justin M Belcher, Steven G Coca, Chirag R Parikh

Journal:

 

Hepatorenal syndrome is a severe complication of cirrhosis and associates with significant mortality. Vasoconstrictor medications improve renal function in patients with hepatorenal syndrome. However, it is unclear to what extent changes in serum creatinine during treatment may act ...

Last Updated: 22 Aug 2015

Go To URL
Renal impairment in cirrhosis unrelated to hepatorenal syndrome.
 

Author(s): Gavin Low, Graeme Jm Alexander, David J Lomas

Journal: Can J Gastroenterol Hepatol. ;29(5):253-7.

 

Renal impairment is common in liver disease and may occur as a consequence of the pathophysiological changes that underpin cirrhosis or secondary to a pre-existing unrelated insult. Nevertheless, the onset of renal impairment often portends a worsening prognosis. Hepatorenal syndrome ...

Last Updated: 16 Jun 2015

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Last Updated: 21 Jun 2017

Go to URL

Last Updated: 2 Jul 2015

Go to URL